Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus

Timar, Romulus; Timar, Bogdan; Degeratu, D; Serafinceanu, Cristian; Oancea, Cristian

doi:10.1177/0300060514541829

Cited by 34 publications

(28 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other investigators have reported that adiponectin levels are higher in patients with type 1 diabetes compared to non-diabetes controls [39–43]. The observations from the current study that adiponectin levels decreased from baseline with both BIL and glargine treatment are also concordant with literature showing that adiponectin levels decline with intensification of insulin treatment [42–44]. In summary, the current data confirm that patients with type 1 diabetes may have high adiponectin levels, but whether lower levels of adiponectin are associated with insulin resistance or clinical cardiovascular disease cannot be confirmed.…”

Section: Discussionsupporting

confidence: 91%

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes

Orchard

Cariou

Connelly

et al. 2017

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundIn Phase 2/3 studies of basal insulin peglispro (BIL) compared to insulin glargine, patients with type 1 or type 2 diabetes previously treated with insulin and randomized to BIL had an increase in serum triglycerides (TGs). To further understand lipoprotein changes, a lipid substudy which included liver fat content was designed to assess relationships among the measured variables for each diabetes cohort and compare the hepato-preferential insulin BIL to glargine.MethodsIn three cohorts of patients with diabetes (type 1, type 2 insulin naïve, and type 2 previously on insulin; n = 652), liver fat content (LFC) was determined by magnetic resonance imaging (MRI) and blood lipids were analyzed by nuclear magnetic resonance (NMR) spectroscopy at baseline, 26 and 52 weeks of treatment. Apolipoproteins, adiponectin, and other lipid parameters were also measured. Descriptive statistics were done, as well as correlation analyses to look for relationships among LFC and lipoproteins or other lipid measures.ResultsIn patients with type 1 diabetes treated with BIL, but not glargine, small LDL and medium and large VLDL subclass concentrations increased from baseline. In patients with type 2 diabetes previously on insulin and treated with BIL, large VLDL concentration increased from baseline. In insulin naïve patients with type 2 diabetes treated with BIL, there were very few changes, while in those treated with glargine, small LDL and large VLDL decreased from baseline. Baseline LFC correlated significantly in one or more cohorts with baseline large VLDL, small LDL, VLDL size, and Apo C3. Changes in LFC by treatment showed generally weak correlations with lipoprotein changes, except for positive correlations with large VLDL and VLDL size. Adiponectin was higher in patients with type 1 diabetes compared to patients with type 2 diabetes, but decreased with treatment with both BIL and glargine.ConclusionsThe lipoprotein changes were in line with the observed changes in serum TGs; i.e., the cohorts experiencing increased TGs and LFC with BIL treatment had decreased LDL size and increased VLDL size. These data and analyses add to the currently available information on the metabolic effects of insulins in a very carefully characterized cohort of patients with diabetes. Clinicaltrials.gov registration numbers and dates NCT01481779 (2011), NCT01435616 (2011), NCT01454284 (2011), NCT01582451 (2012)Electronic supplementary materialThe online version of this article (doi:10.1186/s12933-017-0555-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 91%

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes

Orchard

Cariou

Connelly

et al. 2017

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…Adiponectin can exert both proinflammatory and anti-inflammatory effects [31,32] . In metabolic diseases, TNF-α and IL-6, which are secreted from mast cells in the skin and from macrophages in adipose tissue, are implicated in inhibition of the local production of adiponectin [33,34] .…”

Section: Discussionmentioning

confidence: 99%

Altered Systemic Adipokines in Patients with Chronic Urticaria

Trinh¹,

Pham²,

Ban³

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Increasing evidence suggests that adipokines affect immune responses and chronic urticaria (CU) is associated with an altered immune response related to chronic systemic inflammation. Our objectives were to investigate whether adipokines are involved in CU pathogenesis and to outline relationships between adipokines and urticaria severity and quality of life. Methods: Serum adiponectin, leptin, lipocalin-2 (LCN2), interleukin (IL)-10, IL-6, and tumor necrosis factor (TNF)-α concentrations were measured by enzyme-linked immunosorbent assays in 191 CU patients and 89 healthy controls. The effect of LCN2 on N-formyl-methionine-leucine-phenylalanine (fMLP)-induced neutrophil chemotaxis was assessed using migration assays. CU severity was assessed based on the urticaria activity score (UAS). To explore relationships between adipokines and UAS and the chronic urticaria-specific quality of life (CU-QoL) questionnaire, a structural equation model was used. Results: Mean levels of serum LCN2, TNF-α, IL-6, and IL-10 were significantly higher in CU patients than in controls. Adiponectin levels were significantly lower in patients with CU than in controls. While serum IL-6 levels were significantly higher in refractory CU patients, compared to responsive CU individuals, LCN2 levels were significantly lower. LCN2 inhibited fMLP-induced neutrophil migration. LCN2 showed a direct relationship with UAS (β = -0.274, p < 0.001), and UAS was found to contribute to CU-QoL (β = 0.417, p < 0.001). Conclusions: Our results highlighted an imbalance in pro- and anti-inflammatory adipokines in CU patients. We suggest that LCN2 could be a differential marker for disease activity and the clinical responses to antihistamine treatment in CU patients. Modulation of systemic inflammation may be a therapeutic strategy for treating severe, refractory CU.

show abstract

“…3 The literature revealed that a high insulin dosage was often associated with increased risk of hypoglycemia, weight gain, and, in some cases, the aggravation of cardiovascular risk factors, including dyslipidemia. 4 Metformin is the first-line oral hypoglycemic agent commonly used in the treatment of type 2 diabetes mellitus (T2DM). 5 It decreases the glucose level primarily by suppressing hepatic glucose production (hepatic gluconeogenesis).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Metformin for Patients with Type 1 Diabetes Mellitus: A Meta-Analysis

Liu

Wu²,

Zheng³

et al. 2015

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus

Cited by 34 publications

References 39 publications

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes

Altered Systemic Adipokines in Patients with Chronic Urticaria

Efficacy and Safety of Metformin for Patients with Type 1 Diabetes Mellitus: A Meta-Analysis

Contact Info

Product

Resources

About